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Venous thromboembolism (VTE) is a major health problem among patients with cancer, its incidence in this particular
population is widely increasing. Although VTE is associated with high rates of mortality and morbidity in cancer patients,
its severity is still underestimated by many oncologists. Thromboprophylaxis of VTE now considered as a standard of
care is still not prescribed in many institutions; the appropriate treatment of an established VTE is not yet well known by
many physicians and nurses in the cancer field. Patients are also not well informed about VTE and its consequences.
Many studies and meta-analyses have addressed this question so have many guidelines that dedicated a whole chapter
to clarify and expose different treatment strategies adapted to this particular population. There is a general belief that the
prevention and treatment of VTE cannot be optimized without a complete awareness by oncologists and patients. The
aim of this article is to make VTE a more clear and understood subject.
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Introduction
Cancer is recognized as an independent and major risk
factor for venous thromboembolism (VTE) [1,2]. Ac-
cording to available data and to population-based stud-
ies, cancer is in fact associated with a 4.1-fold greater
risk of thrombosis [3,4]. Also, VTE is associated with a
high potential of morbidity and mortality in cancer pa-
tients [5,6] it is indeed the second leading cause of death
in cancer patients [7]. Occurrence of VTE has been
proven to increase the likelihood of death in cancer pa-
tients by two- to sixfold [5,7].
The association between cancer and thromboembol-
ism was first reported by Trousseau in the nineteenth
century [8], since the awareness of the impact of throm-
botic complications in cancer patients and the need for
early management and prophylaxis is increasing. In our
review, we have found more than 30 practice guidelines
and major reviews on cancer and VTE [9-14].* Correspondence: jihane.khalil@gmail.com; bensaidbadr8@gmail.com
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creativecommons.org/publicdomain/zero/1.0/In contrast, recent surveys have noted low compliance
rates and an underutilization of prophylaxis in hospital-
ized cancer patients [15-18].
In current oncology practice, management and pre-
vention of VTE is frequently encountered; the most
challenging part will be to improve the awareness of the
need of an early detection and management of VTE
before dealing with mortal complications.
In our review, we tried to encompass the most pub-
lished guidelines, meta-analyses, systematic reviews, and
international articles relevant to venous thromboembol-
ism risks prophylaxis, and its management in cancer
patients.Methods
To proceed with the review, we electronically searched
the following databases: the Cochrane Central Register
of Controlled Trials (CENTRAL), MEDLINE (1966 on-
ward; accessed via Ovid), EMBASE (1980 onward; accessed
via Ovid), and ISI Web of Science (February 2010). The
search strategies combined terms relating to venous
thromboembolism, pulmonary embolism, cancer, screening,
diagnosis, management, anticoagulants, prophylaxis, and
treatment.icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Khalil et al. World Journal of Surgical Oncology  (2015) 13:204 Page 2 of 17We also searched the conference proceedings of the
American Society of Clinical Oncology (ASCO, starting
with its first volume, 1982 up to 2015) and of the
American Society of Hematology (ASH, starting with its
2003 issue up to 2015). We also searched in the national
cancer institute database and also in the guidelines from
the European Society of Medical Oncology, National
Institute of health and Care Excellence, the American
College of Chest Physicians, and the European Society of
Cardiology.
We reviewed the reference lists of included papers,
relevant papers, and related systematic reviews.
We used the ‘related citation’ feature in PubMed to
identify additional papers. We also searched Clinical-
Trials.gov (clinicaltrials.gov/) for ongoing studies.
Pathophysiology: how can we explain the frequency of
VTE in patients with cancer?
The pathophysiology of thrombosis associated to cancer
is complex and not entirely understood. Patients with
cancer have a prothrombotic state resulting from the
synergic activity of factors involved in the so-called
Virchow’s triad: stasis of the blood caused by bed rest or
by the tumor compression; vascular injury caused by
intravasation of cancer cells, drugs, or therapeutic de-
vices; and blood hypercoagulability is due to the release
of cancer cell procoagulant factors, which affect the
hemostasis process, including platelet functions and
clotting cascade.
Key roles in pathophysiology are played by tissue fac-
tor (TF), inflammatory cytokines, and platelets.
TF is a transmembrane glycoprotein that has been
identified to be the most likely candidate to explain pro-
coagulant activity in cancer patients. Zwicker et al. eval-
uated the validity of the hypothesis assuming that the
rise in circulating TF-bearing microparticles was associ-
ated with increased risks of VTE in cancer patients [19].
As results, TF-bearing microparticles were found ele-
vated in 60% of cancer patients with VTE and in 27% of
those without VTE, hence predicting an increased risk
of VTE by fourfold
Injured endothelial and cancer cells expose TF on their
membrane; TF is a receptor for the circulating coagulation
factor VII, a serine protease that initiates the blood coagula-
tion cascade, leading to an activation of other serine prote-
ases: coagulation factors X, IX, VIII, V, and thrombin.
Circulating fibrinogen is then conversed into fibrin
monomer, which polymerizes, and forms the fibrin-gel
matrix. This matrix acts as a net, trapping platelets
into a clot that contributes to the tissue repair [20,21].
At last, fibrinolytic enzymes, mostly plasmin, remove
the clot, through the action of urokinase-type plas-
minogen activator (uPA) or tissue-type plasminogen
activator (tPA).In patients with cancer, fibrinolysis is counteracted by
plasminogen-activator inhibitors (PAI) 1 and 2 that are
particularly activated by cancer cells, resulting in en-
hanced chances of developing VTE [22].
Prostacyclin and thromboxane are also released from
injured endothelial and cancer cells; they modulate
platelet adhesion and aggregation [20]. These molecules
are synthesized from arachidonic acid through a multi-
step process involving cyclo-oxygenases 1 (COX-1) and
2 (COX-2) [23].
Platelets also involved in cancer progression and
metastasis have been identified to play a role in the hy-
percoagulable state of cancer [24]. In fact, activated
platelets favor the adhesion of tumor cells to endothelial
cells (EC) leading to their migration through the vessel
wall by the release of heparanase activity. The platelets’
role in cancer progression is explained by their ability to
protect tumor cells from innate immune cells [25].
Platelets’ contribution in tumor growth has been evalu-
ated in many studies; Nierodzik et al. demonstrated in
their study that experimental blockade of key platelet
receptors, such as GP1b/IX/V, GPIIb/IIIa, and GPVI is
associated to a decrease lung colonization of cancer
cells, suggesting attenuation of the metastatic process
[26]. Some recently reported data reported an increased
survival with the use of aspirin in combination with
surgical treatment of non-small cell lung cancer and
colorectal cancer [27,28].
Figure 1 illustrates the contribution of different agents
involved in the pathophysiology of VTE.
Cancer procoagulant (CP) is a cysteine protease only
expressed by malignant cells and amniotic tissue. It has
the particularity to directly activate factor X in the ab-
sence of factor VIIa [19]. CP has also been proven to
stimulate blood platelet adhesion in a mechanism similar
to thrombin and also induces platelet activation [19].
However, in the light of the available evidence, the pre-
cise role of CP in cancer-associated thrombosis remains
not clearly defined.
Vascular injury also found to be involved in the pro-
thrombotic state in patients with cancer is mostly caused
by the treatment prescribed to this specific population.
Chemotherapy for example is known to be associated
with a 4.5- to 6-fold greater risk of thrombosis
depending on the drug used [29]. Cisplatin and
5-fluorouracil, infused for the treatment of gastro-
intestinal tract, cervix, lung, and other cancers, are
thrombogenic [30,31]. Also asparginase, used for the
treatment of acute lymphoblastic leukemia, inhibits
protein synthesis and leads to decreased levels of anti-
coagulant factors leading to an increased risk of VTE.
Of the newer anticancer agents, the immunomodula-
tory drugs (IMiDss, thalidomide, and its analogues)
carry a significant VTE risk [32,33].
Figure 1 Hemostasis genes promote tumor progression. Activated oncogenes (MET*, RAS*), hypoxia-inducible factor-1 (HIF-1), and loss of tumor
suppressor genes (PTEN-, P53-) induce transcriptional programs (nuclear heatmap) including tissue factor (TF), cyclo-oxygenase 2 (COX-2), and
plasminogen-activator inhibitor 1 (PAI-1) upregulation. These, in turn, promote hemostasis activation and fibrin deposition. Fibrin forms a provisional
matrix that favors angiogenesis and supports integrin-mediated cell adhesion and migration. Coagulation proteases activate hepatocyte growth
factor (HGF), and thus the receptor encoded by the MET proto-oncogene (c-MET), which is expressed by endothelial and cancer cells. TF and thrombin
generated by the coagulation cascade activate cell surface receptors (protease-activated receptors [PAR]-1 and −2). COX-2 catalyzes the synthesis of
prostacyclin and thromboxane, which modulate platelet aggregation, and prostaglandin E2 (PGE2). The latter binds cell surface E-series prostaglandin
receptors (EP). Besides inhibiting plasmin and fibrin degradation, PAI-1 promotes integrin recycling. MET, TF, PARs, EP, vascular endothelial growth
factor receptor (VEGFR), and integrins cooperate in regulating cancer cell invasive growth and angiogenesis [23]
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plain the role of chemotherapy in cancer-associated
thrombosis. It mostly includes DNA release from injured
cells [34-37]; platelets are in fact trapped by intravascu-
lar DNA - in form of brands - resulting in a hypercoagu-
lant state. (Table 1 illustrates possible mechanisms of
VTE depending on chemotherapy drug.)
Vessel wall damage can also be caused by extrinsic
vascular compression, either by cancer-associated re-
gional bulky lymphadenopathy or by the use of central
venous access device for chemotherapy infusion [36,37].
Finally, there is the vessel stasis explained by the lon-
ger hospital stay in cancer patients. Heit et al. [38] re-
ported nearly an increase of 22- and 8-fold, respectively,
in the risk of developing VTE in patients hospitalized or
confined to a nursing home with and without recent
surgery.Table 1 Anticancer agents and possible mechanisms for VTE [36,37]
Anticancer or supportive agent Presumed p








Erythropoiesis-stimulating agents Alters plasm
ImiDs (thalidomide, lenalidomide, etc.) EndothelialOther risk factors for VTE are related to patient; age,
for example (>60 years), is associated with a higher risk
of VTE, and obesity and history of anterior VTE have
also been reported to increase risks of VTE [39].
Some factors are related to the cancer itself such as
the tumor’s site. Pancreatic cancer is considered to be
on the top of solid tumors with high risk of VTE. In-
creased risk for VTE has also been noted in certain
hematologic malignancies, such as lymphoma, acute
leukemia, and multiple myeloma [1,40,41].
Histological type and tumor stage have also been de-
fined as risk factors of VTE. Adenocarcinomas are asso-
ciated with higher risks of VTE than squamous cell
carcinomas [42], so is advanced stage as reported by
Blom et al. that found an adjusted odds ratio of 19.8 for
VTE risk in solid tumor cancer patients with distant me-
tastases [43].athomechanism
, arterial, and venous thrombosis
damage, Raynaud’s phenomenon, thrombosis (often combined with
sone as an antiemetic)
a levels of procoagulants and anticoagulants (AT III, protein C, protein S)
a levels of coagulation factors
a levels of coagulation factors
a levels of coagulation factors, increased tissue factor expression
damage, altered plasma levels of F. VIII, von Willebrand factor
Table 3 Predictive KHORANA model for chemotherapy-associated
VTE in ambulatory cancer patients [38]
Risk factors Number
Cancer-related risk factors
Site of cancer and tumor histotype 2
Very high risk (stomach adenocarcinoma, pancreas 1
adenocarcinoma)
High risk (lung, lymphoma, gynecological, bladder,
testicular) 1
Hematological risk factors 1
Prechemotherapy platelet count ±350,000/l 1
Hemoglobin <10 g/dl or use of ESA growth factors
Prechemotherapy leukocyte count >11 000/l 1
Patient-related risk factor
Body mass index ±35 kg/m2
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According to the pathophysiology described above, VTE
risk factors can be grouped in three general categories:
patient-related factors, cancer-related factors, and
treatment-related factors.
Predictive models have been established to assess the
probability of developing VTE according to risk factors.
The ‘Khorana Score’ for example, has been conceived to
estimate the risk of VTE in ambulatory cancer patients
receiving chemotherapy; it includes five predictive
variables, cancer site, platelet count, hemoglobin level (or
the use of erythropoiesis-stimulating agents), leukocyte
count, and body mass index [38] (Tables 2 and 3). This
model has the advantage to be simple and it uses readily
available data [39-42].
Other predictive scores are under evaluation as an ex-
ample PROTECHT Score’ adds platinum and gemcitabine-
based chemotherapy to the predictive variables already
taken into account in the Khorana model [43]. The ‘Ay
Score’ adds D-dimer and soluble p-selectin as additional
discriminatory risk factors for VTE in ambulatory cancer
patients; however, its principal disadvantage is that theTable 2 Risk factors for VTE in cancer patients
Risk factors for VTE in cancer patients





















Other risk factors Leukocyte count
Platelet count
Anemia
Thrombophiliap-selectin is still a research marker and is not readily avail-
able in most laboratories [44]. Finally, there is the ‘Myeloma
Working Group Score’ that is only valid for multiple mye-
loma patients [45].
The principal criticism for these scores is that they are
derived from ambulatory patients receiving chemother-
apy and concerns mostly patients with solid tumors and
with a good performance status.
Validity of these scores to assess the risk for VTE in
patients with poor performance status and those who
are being treated with targeted therapies rather than
‘classical’ chemotherapy is not clear. Moreover, these
predictive models indentify only high-risk patient which
is not sufficient as VTE occurs more often in low-risk
patient [43-48].
Despite these limitations, predictive models help phy-
sicians each day to define right candidates for prophy-
laxis. In fact, American Society of Clinical Oncology
(ASCO) recommends that outpatient candidates for
chemotherapy should be scored according to the Khor-
ana model or other validated scores at the time of
chemotherapy initiation and periodically thereafter [8].
The National Comprehensive Cancer Network (NCCN),
the European Society of Medical Oncology (ESMO), and
the National Institute of Health and Care Excellence
guidelines (NICE) also include the Khorana Score along
with other validated scores as an option to guide the
decision-making regarding prophylaxis outpatients receiv-
ing chemotherapy guidelines [9-12]. However, neither the
American College of Chest Physicians (ACCP) nor the
European Society of Cardiology (ESC)uses those predictive
models to indicate prophylaxis treatment [13,14].
Diagnosis and evaluation of VTE in cancer patients
Like non-cancer patients, classical symptoms of lower
extremity deep venous thrombosis (DVT) include pain,
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veins. In the prospective, multicenter registry (MASTER)
of patients with VTE, the most common presenting
symptoms of DVT were extremity edema, pain, and ery-
thema observed in 80%, 75%, and 26% of patients with
DVT, respectively [49]. However, many cancer patients
with VTE do not have evident symptoms at presentation
as their signs might be masked by the underlying
malignancy.
As to pulmonary embolism (PE), the classic clinical
signs include unexplained shortness of breath, chest
pain, tachycardia, apprehension, tachypnea, syncope, and
hypoxia The clinical presentation of PE can range from
stable hemodynamics to cardiogenic shock. According to
the MASTER registry, the most common presenting
symptoms of PE were dyspnea, pain, and tachypnea,
which were present in 85%, 40%, and 29% of patients
with PE, respectively [49].
Clinical predictive models such as the Wells criteria have
been evaluated and were proven useful in the diagnosis of
VTE [50,51]. In patients with cancer, it is unclear whether
this scoring system is as effective [52]. On one hand, evalu-
ation of these models included only a minority of patients
with cancer, and on the other hand, scoring 1 point is
already given because of the malignancy.
D-dimer testing has been largely used as a diagnostic
tool in non-cancer patients; it has a very good negative
predictive value. In patients with cancer, D-dimer level
could be elevated due to intravascular devices or coagu-
lation activation by the tumor. It has been noted that
the number of false positive D-dimer assays was three-
fold higher in cancer patients when compared to non-
cancer patients [53]. In a large prospective study, D-
dimer levels were high in cancer patients with suspected
DVT while radiologic testing excluded the diagnosis of
VTE [54]. Accordingly, most of the available guidelines
do not suggest D-dimer testing for the diagnosis of VTE
among patients with cancer [10-13], while some others
consider a negative D-dimer test to have the same diag-
nostic value in cancer patient as in non-cancer patients
however, cutoff level to 700 mg/L seems more interest-
ing in this population [14].
Duplex utrasonography remains the number one choice
for the diagnosis of lower extremity venous thrombosis it
allows both an analysis of venous compressibility and
Doppler imaging of venous blood flow [55,56]. Advantages
of ultrasonography, include its accuracy in the diagnosis of
DVT in femoral and popliteal veins without intravenous
contrast agent, its ability to be done at the bedside, and,
above all, its lower cost [56,57]. Its main inconvenient is
that its results are operator-dependent [58].
Other imaging modalities are reserved for specific situ-
ations and can be performed in cases of negative or
indeterminate ultrasound results. Magnetic resonanceimaging (MRI) as an example is commonly used in these
situations, and it is also specific in the evaluation of the
pelvic, iliac veins, and vena cava [55,59,60]. The main
disadvantages of MRI are its higher cost, longer imaging
time duration, and its limited availability in some prac-
tice settings [59].
VTE prophylaxis
Prophylaxis in hospitalized cancer patients
In medical cancer patient To date, there has been no
study evaluating the benefit-risk ratio of thrombopro-
phylaxis conceived exclusively for hospitalized medical
cancer patients.
Five randomized clinical trials including both cancer
and non-cancer patients addressed this question. Three
of them compared low molecular weight heparin
(LMWH) with placebo in hospitalized patients with re-
duced mobility(5% to 15% of cancer patients) [61-63],
and the other two compared LMWH to unfractionned
heparin, all but one of these were double-blind [64,65].
All of these studies concluded that LMWH, unfrac-
tionned heparin (UFH), and fondaparinux were superior
to placebo in preventing VTE, with non-significant in-
creased bleeding risk [61-65].
Consequently, current guidelines recommend prophy-
laxis for hospitalized medical cancer patients [8-13].
LMWH, fondaparinux, or UFH can equally be used
[48-50,61-65]. There is a trend toward to prefer LMWH
and fondaparinux over UFH because of their ease of ad-
ministration. Once started, prophylaxis should be con-
tinued till full recovery or until discharge from hospital
[48-50,65].
In contrast with their high risk of VTE, cancer patients
appear to have a high bleeding risk when compared to
the general population. Therefore, attention should be
paid regarding contraindications and risks associated to
anticoagulation (Table 4).
In surgical cancer patients It is now clearly established
that patients with cancer undergoing surgery are at
higher risk of developing VTE when compared to non-
cancer patients [2,3].
Also in this setting, trials evaluating prophylaxis in pa-
tients undergoing surgery concerned both cancer and
non-cancer patients. Only one randomized controlled
study concerned only cancer patients. It included 99 In-
dian cancer patients undergoing colorectal surgery and
compared LMWH for 6 days with no prophylaxis with
no difference between the two groups [66].
Three meta-analyses compared LMWH or UFH to
placebo; one was conducted in general surgery patients
[67] and the two others concerned patients undergoing
gynecologic surgery [68,69]. The main result was the
superiority of LMWH and UFH over placebo in terms
Table 4 Contraindications to anticoagulation treatment
Contraindications
Absolute contraindications Active major, serious, or potentially life-threatening bleeding not reversible with medical or surgical intervention,
including but not limited to any active bleeding in a critical site (i.e., intracranial, pericardial, retroperitoneal,
intraocular, intra-articular, intraspinal) [10-12a]
-Active bleeding (major): more than 2 units transfused in 24 h, chronic [11,12a]
-Severe, uncontrolled malignant hypertension [10,12a]
-Severe, uncompensated coagulopathy (e.g., liver failure) [10]
-Severe platelet dysfunction or inherited bleeding disorder [10-12a]
-Persistent, severe thrombocytopenia (20,000/L) [10]
-Surgery or invasive procedure, including but not limited to lumbar puncture, spinal anesthesia, and epidural catheter
placement [10-12a]
Relative contraindications -Intracranial or spinal lesion at high risk for bleeding [10-12]
-Active peptic or other GI ulceration at high risk of bleeding [10,12]
-Active but non-life-threatening bleeding (e.g., trace hematuria) [10]
-Intracranial or CNS bleeding within past 4 weeks [10]
-Major surgery or serious bleeding within past 2 weeks [10-12]
-Persistent thrombocytopenia (50,000/L) [10-12]
-Chronic, clinically significant measurable bleeding >48 h [11]
-High risk for falls (head trauma) [11]
aFor ESMO guidelines, all the contraindications are referred as relative
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analysis showed a higher rate of bleeding associated
with LMWH [67].
The question that remains is the choice of the optimal
drug for prophylaxis. Three randomized double-blind
studies tried to answer this question and compared
LMWH with UFH in the prevention of VTE in surgical
patients two of them included exclusively cancer patients
[70,71] and one included 35.2% of cancer patients
undergoing colorectal surgery [72]. Results showed no
difference in terms of effectiveness between LMWH
and UFH. Three other meta-analyses confirmed these
results and reported that UFH given three times a day
is as effective as LMWH given once a day [67,69,73].
In terms of bleeding, both regimens showed the same
results.
Concerning the optimal dose, only one double-blind
trial was conducted it compared subcutaneous 2,500
anti-Xa IU and 5,000 anti-Xa IU of Dalteparin adminis-
tered for 8 days to 1,375 patients undergoing major
elective abdominal surgery, and results showed that
higher doses were more effective [74].
Giving these results, current guidelines have made
specific recommendations concerning postoperative
VTE prevention [8-13] (Table 5). LMWH or UFH are
recommended for VTE prevention in the postopera-
tive setting. Mechanical methods such as pneumatic
calf compression may be added to pharmacological
prophylaxis but should not be used as monotherapy
unless pharmacological prophylaxis is contraindicated.Prophylaxis in ambulatory cancer patients
Nowadays, most cancer patients are being treated as
outpatients as an effort in shortening hospital stays
(Tables 6 and 7).
While recommendations for VTE prevention among
hospitalized patients are clearly established, benefice of
VTE prophylaxis for cancer outpatients is not well-
defined.
To address this question, two prospective randomized
studies compared LMWH with placebo [46,77], PRO-
TECHT (nadroparin, 1,150 patients) and SAVE-ONCO
(semuloparin, 3,212 patients). Both of these studies re-
ported reductions in symptomatic DVT (from 2% to 4%
to 1% to 2%) and PE (from 0.8% to 0.9% to 0.2% to 0.5%)
without increasing the risks of bleeding. Three other
randomized double-blind trials along with an analysis of
pooled data from two other randomized double-blind
studies compared LMWH to placebo [77-84]. Main re-
sults were the decrease of VTE rate in patients with lo-
cally advanced or metastatic pancreatic and lung cancers
when LMWH primary prophylaxis was employed. There
was a trend toward bleeding increase especially in the
context of thrombocytopenia.
According to available data, NCCN panel along with
ESMO, ACCP, and the International Society of throm-
bosis and Haemostasis (ISTH) suggest to evaluate the
risks and benefits of thromboprophylaxis in ambulatory
cancer patients. Predictive models such as the Khorana
model or other validated scores should be used to deter-
mine patients that will benefit most from prophylaxis
Table 5 Summary of international guidelines regarding thromboprophylaxis in hospitalized cancer patients




-Prophylactic anticoagulation therapy(category 1) -Prophylactic anticoagulation therapy (category 1)
± Intermittent pneumatic venous compression device (IPC)
± Graduated compression stockings (GCS) ± Intermittent pneumatic venous compression device (IPC)
± Graduated compression stockings (GCS)
-Out-of-hospital primary VTE prophylaxis is recommended for
up to 4 weeks postoperation (particularly for high-risk abdom-
inal or pelvic cancer surgery patients)
-Mechanical methods are not recommended as monotherapy




1. Hospitalized patients who have active malignancy with acute
medical illness or reduced mobility should receive pharmacologic
thromboprophylaxis in the absence of bleeding or other
contraindications.
1. All patients with malignant disease undergoing major
surgical intervention should be considered for pharmacologic
thromboprophylaxis with either UFH or LMWH unless
contraindicated because of active bleeding or high
bleeding risk.
Evidence: strong Evidence: strong
2. Hospitalized patients who have active malignancy without
additional risk factors may be considered for pharmacologic
thromboprophylaxis in the absence of bleeding or other
contraindications.
2. Prophylaxis should be commenced preoperatively.
Evidence: moderate
Evidence: moderate 3. Mechanical methods may be added to pharmacologic
thromboprophylaxis but should not be used as monotherapy
for VTE prevention unless pharmacologic methods are
contraindicated because of active bleeding or high
bleeding risk.
Evidence: moderate
4. A combined regimen of pharmacologic and mechanical
prophylaxis may improve efficacy, especially in the highest
risk patients.
Evidence: moderate
5. Pharmacologic thromboprophylaxis for patients
undergoing major surgery for cancer should be continued
for at least 7 to 10 days. Extended prophylaxis with LMWH
for up to 4 weeks postoperatively should be considered for
patients undergoing major abdominal or pelvic surgery for
cancer who have high-risk features such as restricted mobility,
obesity, history of VTE, or with additional risk factors. In
lower-risk surgical settings, the decision on appropriate
duration of thromboprophylaxis should be made on a
case-by-case basis considering the individual patient.
Recommendation type, strength: evidence based, strong
3. Data are inadequate to support routine thromboprophylaxis in
patients admitted for minor procedures or short chemotherapy





Prophylaxis with UFH, LMWH or fondaparinux is recommended [I, A]. In cancer patients undergoing major cancer surgery:
Prophylaxis with LMWHs or UFH is recommended.
Mechanical methods such as pneumatic calf compression
may be added to pharmacological prophylaxis but should
not be used as monotherapy unless pharmacological
prophylaxis is contraindicated because of active bleeding [I,A].
Cancer patients undergoing elective major abdominal or
pelvic surgery:
Should receive in hospital and postdischarge prophylaxis with




1. We recommend prophylaxis with LMWH, UFH or fondaparinux in
hospitalized medical patients with cancer and reduced mobility (grade
1B).
1. Use of LMWH once a day or a low dose of UFH three
times a day is recommended to prevent postoperative
VTE in cancer patients; pharmacological prophylaxis should
be started 12 to 2 h preoperatively and continued for
at least 7 to 10 days; there are no data allowing conclusions
regarding the superiority of one type of LMWH over a
nother (grade 1A).
Values and preferences: LMWH once a day is more
convenient
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Table 5 Summary of international guidelines regarding thromboprophylaxis in hospitalized cancer patients (Continued)
2. There is no evidence to support fondaparinux as an
alternative to LMWH for the prophylaxis of postoperative VTE
in cancer patients (grade 2C).
Values and preferences: similar
3. Use of the highest prophylactic dose of LMWH to prevent
postoperative VTE in cancer patients is recommended (grade
1A).
Values and preferences: equal
4. Extended prophylaxis (4 weeks) to prevent postoperative
VTE after major laparotomy in cancer patients may be
indicated in patients with a high VTE risk and low bleeding
risk (grade 2B).
Values and preferences: longer duration of injections
5. The use of LMWH for the prevention of VTE in cancer
patients undergoing laparoscopic surgery may be
recommended in the same way as for laparotomy [best
clinical practice, based on a balance between desirable and
undesirable effects indicating an increased bleeding risk].
Values and preferences: daily injections
Costs: In some countries, the price of LMWH may influence
the choice.
6. Mechanical methods are not recommended as
monotherapy except when pharmacological methods are
contraindicated (grade 2C).




1. For high-VTE-risk patients undergoing abdominal or pelvic
surgery for cancer who are not otherwise at high risk for
major bleeding complications, extended duration pharmaco-
logic prophylaxis (4 weeks) with LMWH over limited-duration
prophylaxis is recommended (grade 1B).
Extended prophylaxis is strongly recommended especially for patients undergoing major abdominal or pelvic surgery [8-13]. This recommendation is based on
the results of two randomized trials and one meta-analysis that showed better outcomes with extended postoperative prophylaxis after major laparotomy
surgery [75,76]
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lung and pancreatic cancer, especially in ESMO and
ISTH guidelines where prophylaxis is systematically rec-
ommended for these localizations [12,14].
For patient with multiple myeloma, the International
Myeloma Working Group recommends prophylaxis with
either LMWH or dose-adjusted warfarin for patients re-
ceiving lenalidomide- or thalidomide-based combination
regimens and also for patients with two or more individual
or disease-related risk factors as defined by the group [41].Treatment of established VTE
Treatment of VTE in general population consists of an
initial treatment with a rapid acting parenteral anticoa-
gulation with LWMH or UFH or fondaparinux overlap-
ping with and followed by an oral vitamin K antagonist
(VKA) (Tables 7 and 8).
Available data suggest that this regimen cannot be ap-
plied for cancer patients, especially because of the higher
risks of bleeding and recurrence in this particular
population.Initial treatment
Initial treatment is defined as the first 10 days of antic-
oagulation treatment.
In our review, we found only retrospective studies in
cancer patients evaluating LWMH or UFH followed by
VKA. Five randomized studies concerned LMWH in as-
sociation with VKA, and six others concerned UFH with
VKA. Overall, recurrence rate was not negligible, and it
reached 6.7% to 16.9% with LMWH and 11% to 38%
with UFH; the two drugs were overlapped and followed
by an oral vitamin K. Major bleeding was also evaluated
up to 10 months of follow-up, and both treatments were
associated with high rates of bleeding [85-88].
Authors concluded that either LMWH or UFH com-
bined to VKA is associated with high rates of recurrence
and bleeding [88]. Therefore, early relay with VKA
should not be advised to this particular population.
As to the choice of the optimal rapid acting parenteral
anticoagulant, we found two meta-analyses of trials com-
paring LMWH and UFH among cancer patients; no stat-
istical difference was found in the rates of recurrence
and major bleeding between the two drugs [88,89]. The
Table 6 Summary of international guidelines related to thromboprophylaxis in ambulatory cancer patients
Summary of international guidelines
NCCN (2014)
[9]
1. Multiple myeloma patients receiving thalidomide or lenalidomide:
-High risk: Recommend anticoagulant VTE prophylaxis
-Low risk: Recommend aspirin
2. Other outpatient settings:
No routine VTE prophylaxis recommended outside of a clinical trial setting
ASCO (2015)
[8]
1. Routine pharmacologic thromboprophylaxis is not recommended in cancer outpatients.
Evidence: moderate.
2. Based on limited RCT data, clinicians may consider LMWH prophylaxis on a case-by-case basis in highly selected outpatients with
solid tumors receiving chemotherapy.
Consideration of such therapy should be accompanied by a discussion with the patient about the uncertainty concerning benefits
and harms as well as dose and duration of prophylaxis in this setting.
Evidence: moderate
3. Patients with multiple myeloma receiving thalidomide- or lenalidomide-based regimens with chemotherapy and/or dexametha-




1. Extensive, routine prophylaxis for advanced cancer patients receiving chemotherapy is not recommended, but may be considered
in high-risk ambulatory cancer patients [II, C].
2. Consider LMWH, aspirin or adjusted-dose warfarin (INR 1.5) in myeloma patients receiving thalidomide plus dexamethasone or
thalidomide plus chemotherapy [II, B].
ISTH (2013)
[12]
1. For children with ALL treated with L-asparaginase, depending on local policy and individual patient characteristics (platelet count,
kidney function, fibrinogen and antithrombin III levels, etc.), prophylaxis may be considered in some patients; the same therapeutic
option can be considered for adults [best clinical practice, based on evidence of very low quality].
2. In patients receiving chemotherapy, prophylaxis is not recommended routinely [grade 1B].
3. Primary pharmacological prophylaxis of VTE may be indicated in patients with locally advanced or metastatic pancreatic cancer
treated with chemotherapy and having a low bleeding risk [grade 1B].
ACCP [13] 1. In outpatients with cancer who have no additional risk factors for VTE, routine prophylaxis with LMWH or LDUH is not suggested
(grade 2B) and the prophylactic use of VKAs is not recommended (grade 1B).
2. In outpatients with cancer and indwelling central venous catheters, routine prophylaxis with LMWH or LDUH is not suggested
(grade 2B), neither is the prophylactic use of VKAs (grade 2C).
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beneficial effect of LMWH on the risk of death; in the
most recent meta-analysis among 801 cancer patients,
the used of LMWH reduced the death rate from 18.9%
to 13.1% with a relative of 0.71 [88].
As to fondaparinux, one randomized controlled trial
compared fondaparinux and LMWH. In a post hoc ana-
lyses of cancer patients’ subgroup, rates of recurrence at
3 months and major bleeding were not different between
the two groups [85,88].
According to these findings, current guidelines recom-
mend either LMWH, UFH, or, in some cases, fondapari-
nux in the initial treatment of VTE [9-14].Early maintenance and long-term treatment of established
VTE
Early maintenance is defined as the period beyond the
tenth day and up to the third month of anticoagulation.
Long-term treatment is the period beyond the third
month of anticoagulation.Six randomized trials and five meta-analyses focused
on long-term treatment of VTE [85-93].
Three of the randomized trials reported that in cancer
patients, extended LMWH treatment was associated
with less VTE recurrence without increasing bleeding
risk [85-87]. The CANTHANOX study added that
LMWH was not only more effective than VKA but also
was associated with a reduced risk of major bleeding at
3 months (P = 0.04) [92].
As to the meta-analyses [89-93], all but one concluded
that early maintenance and long-term treatment with
LMWH decreased the VTE recurrence rate by 50%
[89-93]. No increase in bleeding risk was found in the
extended LMWH treatment arm [90-93].
As a conclusion, in cancer patients with VTE, early
maintenance treatment (10 days to 3 months) and long-
term treatment (beyond 3 months) with LMWH showed
better outcomes in terms of VTE recurrence without
majoring the risk of bleeding.
Current guidelines relied on these results to recom-
mend long-term treatment for 6 months with 75% to





Unfractionated heparin 5,000 U once every 8 h sc
Dalteparin 5,000 U once daily
Enoxaparin 40 mg once daily
Fondaparinux 2.5 mg once daily
Surgical patients
Unfractionated heparin 5,000 U 2 to 4 h preoperatively and once every 8 h sc thereafter or 5,000 U 10 to 12 h preoperatively and 5,000
U once daily thereafter
Dalteparin 2,500 U 2 to 4 h preoperatively and 5,000 U once daily thereafter or 5,000 U 10 to 12 h preoperatively and 5,000
U once daily thereafter
Enoxaparin 20 mg 2 to 4 h preoperatively and 40 mg once daily thereafter or 40 mg 10 to 12 h preoperatively and 40 mg
once daily thereafter
Fondaparinux 2.5 mg beginning 6 to 8 h postoperatively
Treatment of established VTE
Initial
Unfractionated heparin 80 U/kg IV bolus, then 18 U/kg per hour IV
Dalteparin 100 U/kg once every 12 h; 200 U/kg once daily
Enoxaparin 1 mg/kg once every 12 h; 1.5 mg/kg once daily
Tinzaparin 175 U/kg once per day
Fondaparinux 50 kg, 5.0 mg once daily; 50 to 100 kg, 7.5 mg once daily; 100 kg, 10 mg once daily
Long term
Dalteparin 200 U/kg once daily for 1 month, then 150 U/kg once daily
Enoxaparinijk 1.5 mg/kg once daily; 1 mg/kg once every 12 h
Tinzaparin 175 U/kg once daily
Warfarin Adjust dose to maintain INR 2 to 3
Khalil et al. World Journal of Surgical Oncology  (2015) 13:204 Page 10 of 1780% (that is, 150 U/kg once daily) of the initial dose of
LMWH (Table 6 for dosing schedules). Experts consider
this treatment schedule safe and more effective when
compared to early relay with VKA [9-14].
Inferior vena cava filter (VCF)
Inferior vena cave filters (VCFs) are used whenever contra-
indications to anticoagulation are present. Recurrent VTE
despite adequate anticoagulant treatment is another indica-
tion for VCF [9-13]
Fourteen retrospective cohort studies concerned
utilization of vena cava filters in cancer patients, and
their results support the feasibility of placing the vena
cava filter in cancer patients [94-104] technical pre-
cautions should however be taken especially in patient
with metastatic stage.
Idiopathic VTE and cancer screening
Asymptomatic cancers are not uncommon. Spontaneous
VTE can be an alarm signal for underlying malignancy
[105-113].Screening for occult malignancy in patients with symp-
tomatic idiopathic venous thromboembolism (SOMIT) is a
prospective study performed in Italy to assess if an exten-
sive screening program is necessary to identify early stage
in order to improve treatment possibilities and diseases’
prognosis [114]. Results showed that extensive screening
was able to detect most of the hidden malignancies with a
high degree of sensitivity. However, it did not have any im-
pact on overall survival that was the end point of the study.
Other studies succeeded the SOMIT study to address ex-
tensive screening in patient with spontaneous VTE, and
some even considered PET scan [115]. To date, no study
has reported a benefit in survival with extensive screening
[116,117]. A Cochrane meta-analysis has started on No-
vember 2013 and will include all the available trials address-
ing this question; results are still awaited.
ESMO and the NICE are the two available guidelines
that recommend screening programs for occult malig-
nancy in patient with idiopathic VTE.
According to NICE guidelines, physical examination,
chest X-ray, blood tests, and urinalysis should be
Table 8 Summary of available international guidelines concerning the treatment of established VTE
Initial treatment Early maintenance and long term treatment
NCCN (2014) [9] LMWH is recommended for the initial treatment of
established VTE in cancer patients. (Category 1)
1. LMWH (category 1) is preferred for the first 6 months as
monotherapy without warfarin in patients with proximal DVT or PE
and prevention of recurrent VTE in patients with advanced or
metastatic cancer.
2. If warfarin is selected for chronic anticoagulation (category 2b),
initiate warfarin concurrently with the parenteral agent used for
acute therapy and continue both therapies for at least 5 days and
until the INR 2 for 24 h.
During the transition to warfarin monotherapy, the INR should be
measured at least twice weekly. Once the patient is on warfarin
alone, the INR should be measured initially at least once weekly.
Once the patient is on a stable dose of warfarin with an INR
between 2 and 3, INR testing can be gradually decreased to a
frequency no less than once monthly.
ESMO (2011) [10] LMWH is recommended for the initial treatment of
established VTE in cancer patients.
Long-term treatment for 6 months with 75% to
80% (that is, 150 U/kg once daily) of the initial dose of LMWH is safe
and more effective than treatment with a VKA. This schedule is
recommended for Long term anticoagulant therapy in cancer
patients [I, A].
ISTH (2013) [12] 1. LMWH is recommended for the initial treatment of
established VTE in cancer patients [grade 1B].
1. LMWHs are preferred over VKA for the early maintenance
treatment (10 days to 3 months) and long-term treatment (beyond 3
months) of VTE in cancer patients [grade 1A].
Values and preferences: LMWHs are easier to use
than UFH.
2. Fondaparinux and UFH can be also used for the
initial treatment of established VTE in cancer patients
[grade 2D].
Values and preferences: daily subcutaneous injection may represent a
burden for patients.
2. Idraparinux is not recommended for the early maintenance
treatment (10 days to 3 months) and the long-term treatment (be-
yond 3 months) of VTE in cancer patients; idraparinux is currently not
available on the market [grade 2C]. Values and preferences: idrapari-
nux once weekly is easier to use than UFH or LMWH.
Values and preferences: fondaparinux is easier to use
than UFH.
3. LMWH should be used for a minimum of 3 months to treat
established VTE in cancer patients; however, patients were treated for
6 months in the largest study in this setting [grade 1A].
Values and preferences: daily subcutaneous injection may represent a
burden for patients.
4. After 3 to 6 months, termination or continuation of
anticoagulation (LMWH or VKA) should be based on individual
evaluation of the benefit-risk ratio, tolerability, patients’ preference,
and cancer activity [best clinical practice, in the absence of data].
European society of
cardiology (ESC) [14]
LMWH should be administered in the acute phase 1. LMWH administered in the acute phase Should be continued over
the first 3 to 6 months and is considered as first-line therapy.
2. Chronic anticoagulation (beyond 3 months) may consist of
continuation of LMWH, transition to VKA, or discontinuation of
anticoagulation. The decisions should be made on a case-by-case basis.
3. Treatment of cancer-related VTE with fondaparinux and the new




1. In patients with DVT of the leg and cancer, LMWH is suggested
over VKA therapy (grade 2B).
2. In patients with DVT and cancer who are not treated with LMWH,
VKA is suggested over dabigatran or rivaroxaban for long-term ther-
apy (grade 2B).
3. In patients with DVT of the leg and active cancer, if the risk of bleeding
is not high, extended anticoagulant therapy over 3 months of therapy is
recommended (grade 1B), and if there is a high bleeding risk, extended
anticoagulant therapy is suggested (grade 2B).
4. In patients with PE and cancer, the treatment is as suggested in
patient with DVT.
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(abdomino-pelvic CT scan and mammogram for
women) in all patients of 40 years and above with a
first unprovoked DVT or PE who do not have symp-
toms of cancer based on initial investigation [13].
As to ESMO guidelines, patients should undergo physical
examination, chest X-ray, occult fecal blood test, urological
visit in men, and gynecological visit in women. More ex-
pensive examinations such as computed tomography (CT)
scan, digestive endoscopy, or tumor markers should not be
performed unless strong clinical suspicion of occult cancer
is present [12].
Special situations
Patients with brain tumors
Primary central nervous system (CNS) tumors are not
very common; however, their incidence has been in-
creasing over the last 30 years, especially in elderly per-
sons [118]. Metastatic disease to the CNS occurs ten
times more often than primary brain tumors. It is esti-
mated that 20% to 40% of patients with systemic cancer
will develop brain metastases [119].
The specificity of brain tumors is that paradoxically
with their high thrombosis risk, they can be complicated
by hemorrhagic transformation or tumor infiltration of
the spinal cord with a potential risk for intra-spinal
bleeding. Thereby, specific considerations have been
accorded to this localization.
The principal conclusion that was drawn from the few
studies that concerned VTE in patients with brain tu-
mors is that brain tumor per se is not a contraindication
to anticoagulation [120,121]. As to prophylaxis, in
medical patients, benefits and risks have to be weighed
individually using predictive scores such as the Khorana
model to indicate treatment [11-14]. While in surgical pa-
tient, prophylaxis is recommended systematically [11-14].
As for other tumor sites, contraindications have to be eval-
uated before any treatment, and also, monitoring for brain
bleeding should be performed [122]. In patients with estab-
lished VTE, treatment with anticoagulant is recommended
according to the schedule established for other localiza-
tions, and special attention should be paid to the risk of
brain bleeding.
Catheter-related thromboses
In the last two decades, two open-label randomized clin-
ical trials concluded that anticoagulant prophylaxis is
beneficial in reducing VTE risks in patients with central
venous catheter (CVC) [123,124].
However, recent studies do not support this conclu-
sion. In fact, four recent randomized studies suggested
that giving the low incidence of CVC-related VTE
(3% to 4%), systematic prophylaxis was not justified
[125-127].Current guidelines do not recommend routine prophy-
laxis to prevent CVC-related VTE [9-13].
As to the treatment of established VTE, treatment is
as described above. If the catheter is correctly positioned
and functional with no signs of infection and still re-
quired for patient care, guidelines do not recommend
removing the device. Otherwise, CVC should be re-
moved and also in the case of VTE recurrence despite
an adequate anticoagulation [9].
Other special situations
Patients with renal insufficiency Dosage adjustments
for renal failure are available and should be applied for
each approved LMWHs’ treatment on a case-by-case
basis and according each case creatinine clearance.
In patients with severe renal failure (creatinine clear-
ance <30 mL min), UFH can be used on a case-by-case
basis [9,14].
Patients with thrombocytopenia Full doses of anti-
coagulant can be used for the treatment of established
VTE if the platelet count is >50 G L. There is no evi-
dence of a major risk of bleeding when platelet count is
below 50 G L, and decisions on treatment and dosage
should be made on a case-by-case basis with the utmost
caution [8-14].
Anticoagulant as a cancer treatment in patients without
VTE
As described, there are many interactions between co-
agulation activation and tumor growth; blocking the
clotting cascade with anticoagulant agents can lead to a
disruption of the tumor proliferation process [128,129].
Accordingly, we can assume that anticoagulation may
have some antitumor activity [130-133].
Few clinical trials and some limited case reports ad-
dressed this question [134-143]. While older reports
suggested a beneficial effect of anticoagulation, the
newer studies did not support this conclusion [144-147].
A Cochrane meta-analysis included nine RCTs enrol-
ling 2,857 patients. Heparin, either unfractionated hep-
arin or low molecular weight heparin, was evaluated in
all of the included RCTs [148]. Authors concluded that
heparin was associated with a significant reduction of
death at 24 months but not at 12 months. Anticoagula-
tion was also associated with a reduction in venous
thromboembolism with no significant effect on major
bleeding, minor bleeding, or quality of life (QoL).
Future research should further investigate the survival
benefit of different types of anticoagulants in patients
with different cancer types and stages of cancer. Deci-
sion to prescribe anticoagulation for cancer patients
without VTE should balance benefits and risks and also
integrate patient values and preferences [148].
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New oral anticoagulants (NOACs) are a new achieve-
ment in the management of thrombosis; they directly in-
hibit factor Xa or thrombin. These agents are very
attractive as they can be taken orally, without the need
of dose adjustment, they also do not have drug interac-
tions, and moreover, they do not require monitoring.
Dabigatran, a direct thrombin inhibitor, and rivaroxaban
and apixaban, two direct factor Xa inhibitors, are the
most developed agents.
In non-cancer patients, these drugs have proven their
effectiveness in VTE prophylaxis in the postoperative
setting also in stroke prevention in patients with non-
valvular atrial fibrillation [149]. Moreover, they have
been shown to be effective in the prevention of recur-
rent VTE. Rivaroxaban has in fact been approved as
monotherapy in the treatment of DVT [149-151].
Studies evaluating NOACs in medical patients in-
cluded small numbers of patients with cancer. No stud-
ies have specifically evaluated the treatment of cancer-
associated VTE using these agents. Only a small phase 2
study evaluated the safety and tolerability of apixaban in
patients with cancer. Authors reported low risk of major
bleeding (2.2%) during 12 weeks of therapy in 125 pa-
tients with metastatic or advanced cancer without
thrombosis [152].
In a subgroup analysis of thromboprophylaxis with rivar-
oxaban, a trend to less efficacy although not significant -
was noted in the enoxaparin arm among patients with
active cancer [153]. In another subgroup analysis of a rivar-
oxaban trial, the reported results were different; rivaroxaban
was associated with a (non-significant) reduction of VTE
and less bleeding. The main criticism of this study is that
VKA was the comparator used which is not considered as
the optimal choice for cancer patients [154].
Giving this limited data, current guidelines do not recom-
mend the routine use of NOACs either in VTE prophylaxis
or in the treatment of established VTE [8-13].
Conclusions
In 2002, a survey among oncologists in northern Eng-
land found that more than a quarter of oncologists do
not recognize the thrombogenic effects of the treatments
prescribed to patients with cancer. Other surveys have
also made the conclusion that VTE in patients with can-
cer is being underestimated and thromboprophylaxis is
rarely prescribed. Since, interest has been accorded to
VTE in patients with cancer especially that higher rates
of recurrence and major bleeding have been noted for
this population.
Nowadays, guidelines have been established to im-
prove the management and outcomes for cancer patients
with VTE, and the question of VTE in cancer patient
has become more clarified, especially regarding theprophylaxis. In fact, prophylactic anticoagulation therapy
is recommended for all inpatients with a diagnosis of ac-
tive cancer who do not have a contraindication to such
therapy.
For surgical outpatients, extended prophylaxis (4 weeks)
with LMWH is recommended over limited duration
prophylaxis for patients undergoing abdominal or pelvic
surgery who are not otherwise at high risk for major bleed-
ing complications.
As to medical outpatients, prophylaxis is given after
an evaluation of the benefits and risks of anticoagulation;
predictive models such as the Khorana model might be
used to select appropriate candidates for prophylaxis.
It is the time for us, physicians to change our clinical
daily practice.
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